SCHEMBL3898337

SCHEMBL3898337

CC(C#N)(NC(=O)C(CC1CC1)OC(=O)N1CCc2ccccc2C1)OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABHD6 Q9BV23 1/20 0.41
MMP8 P22894 1/20 0.41
KDM4E B2RXH2 2/20 0.40
RECQL P46063 1/20 0.39
DPP4 P27487 3/20 0.38
DPP8 Q6V1X1 2/20 0.38
DPP7 Q9UHL4 2/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
TMEM97 Q5BJF2 3/20 0.37
SIGMAR1 Q99720 3/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
ALDH1A1 P00352 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
DRD2 P14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3909384 0.90 ABHD6 (0.44) ABHD6MMP8KDM4ERECQLTMEM97
SCHEMBL3898451 0.88 ABHD6 (0.42) ABHD6MMP8KDM4ERECQLCTSL
SCHEMBL3899406 0.88 ABHD6 (0.42) ABHD6MMP8KDM4ERECQLCTSK
SCHEMBL3910427 0.88 ABHD6 (0.45) ABHD6MMP8KDM4ERECQLDPP4
SCHEMBL3895583 0.88 ABHD6 (0.46) ABHD6MMP8KDM4ERECQLDPP4
SCHEMBL3894601 0.86 ABHD6 (0.45) ABHD6MMP8KDM4ERECQLDPP4
SCHEMBL3903519 0.86 CTSS (0.46) CTSLCTSBCTSSCTSKALDH1A1
SCHEMBL3898182 0.82 CTSS (0.52) CTSLCTSBCTSSCTSK
SCHEMBL3909361 0.82 CTSS (0.41) CTSLCTSBCTSSCTSKALDH1A1
SCHEMBL3895788 0.81 CTSS (0.44) CTSLCTSBCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399431-B1 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMA (US) 2009-02-18 EP claimed
US-6982263-B2 Nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-01-03 US claimed
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-06-26 US claimed
WO-2002100849-A2 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-12-19 WO claimed
EP-1399431-B1 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMA (US) 2009-02-18 EP disclosed
US-6982263-B2 Nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-01-03 US disclosed
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases NOS1, CTSK, CTSS ABHD6 4134/4885MMP8 60/4885KDM4E 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.